Abbott Brushes Off Procedure Volume Concerns, Lifts Outlook
Abbott Laboratories (NYSE: ABT ) stock rose Thursday after the healthcare company reported second-quarter 2026 results that beat Wall Street estimates on both earnings and revenue and raised its full-year adjusted earnings outlook. Adjusted earnings came in at $1.31 per share, topping the analyst consensus estimate of